CD274 and colorectal carcinoma: In summary, we present an all-in-one polymer chimera based on stapled oncolytic peptide for targeted oncolysis and synergistic ICB therapy, addressing the insensitivity of CRC to anti-PD-L1 immunotherapy due to neoantigen deficiency.